Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
Diseases of the Digestive System - Liver
What is the purpose of this trial?
This research study is for people who may have abnormally high amount of fat and swelling (inflammation) of their liver along with some fibrosis (scarring) that is not related to excessive alcohol consumption. The medical term for this condition is nonalcoholic steatohepatitis (NASH) that has both high liver fat and inflammation (swelling) and fibrosis (scarring) that causes a stiff liver. This research study involves two investigational drugs (study drugs) as potential options to treat patients with NASH with liver fibrosis.
- Ages18 years - 75 years
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date01/08/2021
- End Date11/01/2022
- Last Updated07/26/2021
- Study HIC#2000027577